Press Releases

Following a national search, Roswell Park Comprehensive Cancer Center has appointed Marco Davila, MD, PhD, as Senior Vice President and Associate Director for Translational Research and Vice Chair for Cellular Therapies.

An accomplished research leader with a record of important discoveries in cancer biology and precision therapeutics, Roswell Park Comprehensive Cancer Center’s Erik Knudsen, PhD, has been promoted to Associate Director of Basic Science Research.

To improve career pathways for students in the health sciences, Roswell Park Comprehensive Cancer Center and Trocaire College have partnered to launch the Roswell Scholars program.

A brain cancer vaccine developed at Roswell Park Comprehensive Cancer Center — SurVaxM — is being utilized in a pilot study in children and adolescents marking the first clinical trial of the immunotherapy in a pediatric population. The multicenter trial is sponsored by the Pediatric Brain Tumor Consortium

On June 7, in a talk at the ASCO Annual Meeting 2022, Eunice Wang, MD, will present the long-term results of a phase 2 clinical trial combining crenolanib with standard intensive chemotherapy for treatment of adults with newly diagnosed FLT3-mutant acute myeloid leukemia (AML).

Roswell Park Professor of Neurosurgery Michael Ciesielski, PhD, is presenting the most recent findings from the completed phase 2A study of the immunotherapy SurVaxM at a poster session tomorrow, June 5, at the American Society of Clinical Oncology (ASCO) 2022 annual meeting. The largest clinical cancer meeting in the world, the conference continues through June 7 in Chicago.

New research led by Kara Kelly, MD, of Roswell Park and presented at the American Society of Clinical Oncology 2022 Annual Meeting in Chicago shows that a combination of brentuximab vedotin (Bv) and standard chemotherapy is safe and more effective than standard chemotherapy in pediatric patients up to age 21 years with newly diagnosed high-risk Hodgkin lymphoma.

A team of researchers at Roswell Park Comprehensive Cancer Center, led by Dhyan Chandra, PhD, have uncovered evidence that could lead to the development of a new treatment option for patients with metastatic, resistant or recurrent prostate cancer. Their findings, published today in the Journal of Clinical Investigation, suggest that mitochondrial unfolded protein response — a unique longevity function of mitochondria — could be a new target for the treatment and management of this patient population.

Researchers from Roswell Park Comprehensive Cancer Center will present the latest results of clinical trials and insights on cancer treatment and issues affecting patients with cancer, including the financial burdens induced by cancer treatment, at the annual meeting of the American Society of Clinical Oncology (ASCO), which will take place both online and in-person in Chicago, Illinois, from June 3 to 7.